The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
Anthony B. El-Khoueiry
No relevant relationships to disclose
Yan Ning
No relevant relationships to disclose
Dongyun Yang
No relevant relationships to disclose
Sarah Cole
No relevant relationships to disclose
Michael Kahn
Consultant or Advisory Role - PRISM Pharma
Stock Ownership - PRISM Pharma
Research Funding - PRISM Pharma
Marwan Zoghbi
No relevant relationships to disclose
Jennifer Berg
No relevant relationships to disclose
Masamoto Fujimori
Employment or Leadership Position - PRISM Pharma
Stock Ownership - PRISM Pharma
Tetsuhi Inada
Employment or Leadership Position - PRISM Pharma
Stock Ownership - PRISM Pharma
Hiroyuki Kouji
Employment or Leadership Position - PRISM Pharma
Stock Ownership - PRISM Pharma
Heinz-Josef Lenz
No relevant relationships to disclose